<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03926754</url>
  </required_header>
  <id_info>
    <org_study_id>2016-002367-34</org_study_id>
    <secondary_id>H-16030780</secondary_id>
    <nct_id>NCT03926754</nct_id>
  </id_info>
  <brief_title>Beta 3 Agonist Treatment in Heart Failure-2</brief_title>
  <acronym>BEAT-HF II</acronym>
  <official_title>Beta 3 Agonist Treatment in Heart Failure-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henning Bundgaard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bispebjerg-Frederiksberg Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillerød hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bornholm Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal North Shore Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: The objective of the study is to assess the structural and functional cardiac
      effects of treatment with the beta 3 AR agonist Mirabegron in patients with moderate to
      severe chronic heart failure (LVEF&lt;35%, NYHA III-IV).

      The study is a randomized, placebo‐controlled, double‐blinded trial in two phases with two
      hypotheses:

      Chronic study - study A: Long-term treatment (3 months) with the β3 adrenergic receptor
      agonist Mirabegron is beneficial in patients with moderate to severe human heart failure

      Invasive study - Study B: Administration of Mirabegron in patients with heart failure leads
      to an immediate increase in cardiac output at a constant or reduced left ventricular filling
      pressure during submaximal exercise

      Specific aims

        1. Determine safety of administration of Mirabegron to patients with moderate to severe
           heart failure.

        2. Determine if treatment with Mirabegron for 3 months induces beneficial cardiac
           structural remodelling in patients with moderate to severe heart failure. In an
           open-label follow-up to determine the effects of Mirabegron after an extended duration
           (a total of 12 months).

        3. Determine if Mirabegron improves symptoms and exercise capacity as indicated by
           questionnaires and 6 min walk test in patients with moderate to severe heart failure.

        4. Determine effects of Mirabegron on cardiac conduction, repolarisation and rhythms and
           arrhythmias in patients with moderate to severe heart failure.

        5. Determine effects of Mirabegron on circulating biomarkers in patients with moderate to
           severe heart failure.

        6. Determine the immediate and short term haemodynamic effects of Mirabron as measured by
           CT and invasively.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 23, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in left ventricular ejection fraction as measured by computed tomography</measure>
    <time_frame>3 months</time_frame>
    <description>Study A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in invasive hemodynamics assesses by right heart catherization</measure>
    <time_frame>At 3 hours and at 1 week</time_frame>
    <description>Study B is explorative assessing the effect on invasive parameters including cardiac output, pulmonary wedge pressure and pulmonary and systemic vascular resistance.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction NYHA Class III-IV</condition>
  <arm_group>
    <arm_group_label>Mirabegron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active treatment arm (mirabegron)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.
Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days).</description>
    <arm_group_label>Mirabegron</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Stable heart failure NYHA class III-IV on ischemic or non-ischemic basis

          2. Left ventricular ejection fraction (LVEF) &lt; 35% as assessed by cardiac CT

          3. NT proBNP &gt; 1000 pg/ml

          4. On optimised evidence-based pharmacological HF treatment stable ≥2 weeks with no
             current plan for changing HF therapy. The therapy must include a beta-blocker.

          5. No change in diuretics ≤1 week

          6. No admittances to hospital for treatment with intravenously administered positive
             inotropic agents ≤ 4 weeks.

          7. &gt;18 years

        Exclusion Criteria:

          1. Acute myocardial infarction (AMI) or revascularisation &lt; 3 month ago

          2. Uncorrected significant primary obstructive valve disease

          3. Planned major surgery including cardiac revascularisation

          4. Hemodynamically significant obstructive cardiomyopathy

          5. Acute myocarditis or constrictive pericarditis

          6. Clinically significant hepatic (transaminases or bilirubin x 3 above upper reference
             level) or renal (GFR&lt; 30 ml/min/1,73 m2) diseases

          7. Heart failure due to uncorrected thyroid disease

          8. Cardiac mechanical support

          9. &lt; 6 months after CRT

         10. Uncontrolled hypotension (defined as symptomatic systolic blood pressure &lt; 80 mmHg) -
             or hypertension (defined as systolic at 180 mmHg or above and/or diastolic blood
             pressure at 110 mmHg or below)

         11. Unable to give informed consent

         12. Reduced compliance

         13. All women of child bearing potential will be required to use adequate contraception

         14. Pregnant or lactating women

         15. Treatment with a tricyclic antidepressant or CYP2D6 substrates other than
             beta-blockers or treatment with digoxin.

         16. Known allergy to iodine containing contrast

         17. Estimated GFR &lt; 30 ml/min/1.73 m2

         18. Congenital or drug induced QT prolongation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Bundgaard H, Axelsson A, Hartvig Thomsen J, Sørgaard M, Kofoed KF, Hasselbalch R, Fry NA, Valeur N, Boesgaard S, Gustafsson F, Køber L, Iversen K, Rasmussen HH. The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial. Eur J Heart Fail. 2017 Apr;19(4):566-575. doi: 10.1002/ejhf.714. Epub 2016 Dec 18.</citation>
    <PMID>27990717</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Henning Bundgaard</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

